Preclinical Alzheimer's disease
Disease1 paper
- Humans1
Trial sponsors
Company1 trialPhase 31,400 people
1 trialPhase 2450 people
Funding
National Institute on AgingUS$8m15 grants since 2017
National Institute on AgingColumbia University Health SciencesUS$132.3k2026–2028
Grit against cognitive decline in aging and preclinical Alzheimer Disease
National Institute on AgingMassachusetts General HospitalUS$831.2k2024–2029
National Institute on AgingTufts University BostonUS$660k2026–2029
National Institute on AgingArizona State University-tempe CampusUS$50.1k2026–2028
National Institute on AgingUniversity of PennsylvaniaUS$706.1k2017–2027
Linking basal forebrain and entorhinal cortex vulnerability to preclinical Alzheimer's disease
National Institute on AgingUniversity of California, BerkeleyUS$131.3k2022–2027
National Institute on AgingBoston University Medical CampusUS$558.1k2021–2027
National Institute on AgingMayo Clinic RochesterUS$576.2k2025–2030
National Institute on AgingWashington UniversityUS$129.9k2026–2031
National Institute on AgingUniversity of Rhode IslandUS$2m2022–2027
Latest
56Exploratory Analysis of APOE ε4-Stratified Associations Between Plasma Alzheimer's Biomarkers and Retinal Imaging Metrics in Cognitively Normal Adults
App knock-in mice display age-dependent Alzheimer's pathology
In a study of App SAA knock-in mice from 4 to 19 months, animals developed progressive amyloid pathology, neuroinflammation, biomarker shifts, and…In a study of App SAA knock-in mice from 4 to 19 months, animals developed progressive amyloid pathology, neuroinflammation, biomarker shifts, and synaptic loss.